The Cohort Study of Uveitis Patients
NCT05727540 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2024-08-23
Summary
This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.
Conditions
- Uveitis
Sponsors & Collaborators
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-20
- Primary Completion
- 2026-02-20
- Completion
- 2026-03-31
Countries
- China
Study Locations
More Related Trials
-
Immune Indicators of Uveitis
NCT00089739 ·Status: COMPLETED
-
Biomarkers in Ocular Inflammation and Uveitis
NCT04690829 ·Status: COMPLETED
-
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
NCT05385757 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis
NCT04798755 ·Status: UNKNOWN ·Phase: PHASE3
-
Outcome of Treatment of Uveitis With Biologic Drugs in Resistant Cases Vogt-koyanagi-Harada Disease
NCT05349747 ·Status: UNKNOWN
-
Microbiome as a ThErapeutic Response Biomarker
NCT04721743 ·Status: WITHDRAWN
-
Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients
NCT05155592 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01032915 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy of AIN457 in Noninfectious Uveitis
NCT00685399 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
NCT05105347 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01090310 ·Status: TERMINATED ·Phase: PHASE3
-
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01103024 ·Status: WITHDRAWN ·Phase: PHASE3
-
Analysis of Eye Tissue
NCT00001224 ·Status: COMPLETED
-
Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma
NCT03571282 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
NCT00331331 ·Status: COMPLETED
-
First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
NCT01232920 ·Status: COMPLETED ·Phase: PHASE3
-
Metagenomics for Ocular Inflammation
NCT06974162 ·Status: RECRUITING
-
Treatment FOr Corticosteroid Dependent UveitiS
NCT06258915 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
NCT01327664 ·Status: WITHDRAWN ·Phase: PHASE3
-
Uveitis Gene-Expression Profiling
NCT00874471 ·Status: COMPLETED
-
"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
NCT05874505 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study
NCT01261169 ·Status: UNKNOWN
-
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00070759 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
NCT01684345 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
NCT07218770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2